

PROGRAM

WEDNESDAY 18 OCTOBER 2017

8:30	Workshop opening & HBV update
Session 1 Clinical Update on HBV Cure	
8:35	TAF – The latest update, which questions remain to be answered? Pietro Lampertico - University of Milan, Milan, Italy
8:50	Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement Fabien Zoulim - INSERM ,Paris, France
9:05	Is immunomodulation really needed to cure HBV? Heiner Wedemeyer - Medical School Hannover, Hannover, Germany
9:20	Discussion
9:40	Coffee break
Session 2 New biomarkers: how will they help us?	
10:10	How to use new virological biomarkers to assess HBV cure: quantitative HBsAg, HBcrAg, HBV-RNA Thomas Berg (tbc) - University of Leipzig, Leipzig, Germany
10:25	To look inside or outside of the liver for evidence of HBV cure? Georg Lauer - Massachusetts General Hospital, Boston, MA, USA
10:40	Discussion
Session 3 New Treatment modalities - Immunologic response	
11:00	How does HBV interact with the immune system Mala Maini - University College London, London, United Kingdom
11:15	Innate Immunity : TLR, RIG-I, STING and potential others Adam Gehring - University of Toronto , Toronto, Canada
11:30	Adaptive Immunity: Therapeutic vaccination, checkpoint inhibition and potential others Andre Boonstra (tbc) - Erasmus Medical Center, Rotterdam, the Netherlands
11:45	Panel discussion
12:15	Lunch

4th INTERNATIONAL HBV CURE WORKSHOP

TORONTO, CANADA • 18 OCTOBER 2017



Session 4 New Treatment modalities - Virological challenges	
13:15	Entry inhibition Stefan Urban (tbc) - Heidelberg University, Heidelberg, Germany
13:25	CCC – DNA inhibition Anuj Gaggar - Gilead Sciences, Foster City, USA
13:35	RNA interference Bill Symonds - Arbutus, Burnaby, Canada
13:45	Capsid inhibition Angela Lam (tbc) - Novira Therapeutics, Doylestown, PA, USA
13:55	HBV Ribonuclease H John Tavis - Saint Louis University School of Medicine, Saint Louis, MO, USA
14:05	Other virologic mechanisms Stephen Locarnini - Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia
14:15	Roundtable discussion
15:00	Coffee break
Session 5 From the science to the clinic	
15:30	Is personalized therapy needed to achieve success? Marion Peters - University of California, San Francisco, CA, USA
15:50	Combination therapy how to navigate in a minefield of efficacy and toxicity? Jordan Feld - Toronto Centre for Liver Disease, Toronto, Canada
16:10	Innovative trial design Henry Lik Yuen Chan - Chinese University of Hong Kong, Hong Kong
16:30	Round table discussion: Trial design, treatment endpoints and regulatory approach
17:30	Closure of the Workshop

More information and registration:
www.virology-education.com
info@virology-education.com